Sanofi Refocuses Its Business on Mature and Emerging Markets
The company announced it is creating a new Primary Care global business unit and a China & Emerging Markets unit.
On Sept. 13, 2018, Sanofi announced it will change the organization of two of its global business units (GBU) to create a new Primary Care GBU and a China & Emerging Markets GBU. The new GBUs will launch by the beginning of 2019.
The new Primary Care GBU will focus on mature markets and will combine the existing Diabetes and Cardiovascular (DCV) GBU with Established Products, which are currently part of the General Medicines & Emerging Markets (GEM) GBU. Dieter Weinand will be appointed as executive vice president, effective November 1, 2018, and will report directly to Sanofi CEO Olivier Brandicourt and become a member of the Executive Committee.
The China & Emerging Markets GBU will focus on emerging markets with growth opportunity, such as Chia, and will be led by Olivier Charmeil, currently head of the GEM GBU. China is Sanofi’s second largest market after United States.
The company stated in a press release that Sanofi Genzyme, Sanofi Pasteur, and Consumer Healthcare will not change.
Source: Sanofi
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
